Cantor Morning News | Healthcare

S&P 500 Futures held the 1068/1069 level which was Monday's low. They are already traded below that number. 1065/1060 should show first signs of support ahead of 1050 area which would be a 61.8% retrace of recent move. If there is a breach of the 1050 level look for accelerated down ward move eventually to 1006 level.

HMO Index broke its 200 day m/a starting c wave of A-B-C correction look for further weakness with support in the 1420 area

DRG Index weak with rest of market yesterday .Abreach of the 280 price zone would begin a C wave in a A-B-C corrective pattern with a price target of 220

Macro/Technicals

HMO: 1459.11; -2.68
DRG: 286.46; -1.30
XLV: 28.770; -1.84

Leaders: ENDP 2.46%
Laggards: AFFX - 9.25 VVUS -6.54% IMGN -5.82%

Active Names

Active Names

Biotech/Pharma: MNKD, STEM

Healthcare Services: ABC, ATHN, FURX,ROHI, HLS, RAD

Restaurants/Publishing/Retail: DPZ,SONC

Sector News, M&A, Capital Raises

JAZZ Follow-up: Jazz Pharmaceuticals halted ($10.23)
StreetAccount notes that an the FDA's Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee is meeting today to consider Jazz Pharmaceuticals' sodium oxybate oral solution (proposed name Rekinla), indicated for the treatment of fibromyalgia. Shares of JAZZ will likely be halted all day.

Research Away

THOR Soleil comments on Thoratec, proposed expanded coverage for VADs for destination therapy ($33.89)
CMS last night proposed expanded coverage for ventricular assist devices for destination therapy, easing three criteria for reimbursement (peak VO2, medical management, and body size). Soleil notes that CMS did not accept THOR's request to expand VAD coverage to include less sick Class IIIb DT heart failure patients and says this is reflected in current valuation. If finalized, the expanded indications should increase the % of referred DT patients that are eligible and implanted with VADs.

Disclaimer: Prepared by staff of Cantor Fitzgerald & Co. ("Cantor") and is for information purposes only. It is not intended to form the basis of any investment decision, should not be considered a recommendation by Cantor or any other person and does not constitute an offer or solicitation with respect to the purchase or sale of any investment nor is it a confirmation of terms. Any calculations and valuations presented herein are intended as a basis for discussion. Sources of information are believed to be reliable but Cantor makes no representation and gives no warranty that the information contained herein is accurate or complete. Any opinions or estimates given may change. Cantor undertakes no obligation to provide recipients with any additional information or any update to or correction of the information contained herein. This material is intended solely for institutional investors and investors who Cantor reasonably believes are institutional investors. Cantor, its officers, employees, affiliates and partners shall not be liable to any person in any way whatsoever for any losses, costs or claims howsoever arising from any inaccuracies or omissions in the information contained herein or any reliance on that information. Cantor may have positions in financial instruments mentioned, may have acquired such positions at prices no longer available, and may have interests different or adverse to your interests. No liability is accepted by Cantor for any loss that may arise from any use of the information contained herein or derived here from. This product may not be reproduced or redistributed outside the recipient's organization. Sources: Cantor Fitzgerald & Co., Reuters, Bloomberg, CNBC, Dow Jones, Marketwatch, Trade-Alert, and the Wall Street Journal. ***All eco data from Bloomberg and DJ